Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:BDTX NASDAQ:ETHZ NASDAQ:QUCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.16+2.5%$4.10$1.21▼$3.81$102.74M0.68261,100 shs161,368 shsBDTXBlack Diamond Therapeutics$1.75$2.60$1.75▼$4.94$100.28M3.222.26 million shs2.31 million shsETHZFlag Ship Acquisition$5.35+1.1%$4.07$0.70▼$17.46$101.71M1.176.44 million shs300,160 shsQUCYMainz Biomed$1.73$1.46$0.30▼$4.93$25.36M2.2210.08 million shs2.14 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.24%-18.43%+6.39%+112.24%BDTXBlack Diamond Therapeutics0.00%-11.17%-36.36%-20.09%-24.24%ETHZFlag Ship Acquisition0.00%+5.11%+9.86%+85.12%+534,999,900.00%QUCYMainz Biomed0.00%-21.36%-50.00%+150.11%+172,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.16+2.5%$4.10$1.21▼$3.81$102.74M0.68261,100 shs161,368 shsBDTXBlack Diamond Therapeutics$1.75$2.60$1.75▼$4.94$100.28M3.222.26 million shs2.31 million shsETHZFlag Ship Acquisition$5.35+1.1%$4.07$0.70▼$17.46$101.71M1.176.44 million shs300,160 shsQUCYMainz Biomed$1.73$1.46$0.30▼$4.93$25.36M2.2210.08 million shs2.14 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.24%-18.43%+6.39%+112.24%BDTXBlack Diamond Therapeutics0.00%-11.17%-36.36%-20.09%-24.24%ETHZFlag Ship Acquisition0.00%+5.11%+9.86%+85.12%+534,999,900.00%QUCYMainz Biomed0.00%-21.36%-50.00%+150.11%+172,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/ABDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00471.43% UpsideETHZFlag Ship Acquisition 1.00SellN/AN/AQUCYMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest QUCY, ETHZ, BDTX, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/11/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/27/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)3/17/2026BDTXBlack Diamond Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M4.10N/AN/A$4.29 per share0.97BDTXBlack Diamond Therapeutics$70M1.43$0.53 per share3.32$1.97 per share0.89ETHZFlag Ship Acquisition$4.11M24.75N/AN/A$29.12 per share0.18QUCYMainz Biomed$537.08K47.22N/AN/A$0.07 per share24.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/ABDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)ETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/AQUCYMainz Biomed-$16.21M-$47.60N/AN/AN/AN/AN/AN/AN/ALatest QUCY, ETHZ, BDTX, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A3/31/2026Q4 2025QUCYMainz BiomedN/A-$0.0250N/A-$0.0250N/A$0.13 million3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AQUCYMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54BDTXBlack Diamond TherapeuticsN/A8.468.46ETHZFlag Ship Acquisition1.1110.0710.07QUCYMainz BiomedN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%BDTXBlack Diamond Therapeutics95.47%ETHZFlag Ship Acquisition4.07%QUCYMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%BDTXBlack Diamond Therapeutics9.29%ETHZFlag Ship Acquisition15.10%QUCYMainz Biomed3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionNo DataBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableETHZFlag Ship Acquisition719.01 million16.14 millionN/AQUCYMainz Biomed3014.66 million14.21 millionN/AQUCY, ETHZ, BDTX, and AADI HeadlinesRecent News About These CompaniesQuantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense Platform1 hour ago | globenewswire.comQuantum Cyber Terminates At-the-Market Facility, Citing Strengthened Financial Position and No Immediate Capital NeedsJune 12 at 8:30 AM | globenewswire.comQuantum Cyber Entering Steady-State Scale Production, Launches Vertically Integrated Advanced Filament Manufacturing DivisionJune 11, 2026 | globenewswire.comQuantum Cyber Signs LOI to Acquire an Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility to Support Mass-Scale Autonomous Drone ProductionJune 8, 2026 | globenewswire.comMainz Biomed (NASDAQ:QUCY) Upgraded at Wall Street ZenJune 6, 2026 | americanbankingnews.comQuantum Cyber Publishes Inaugural Corporate Investor Presentation Showcasing System-of-Systems Autonomous Defense Platform, Eight Filed Patent Positions, LOIs With General Cherry and SOCOM, and $15 Million Debt-Free Balance SheetJune 3, 2026 | globenewswire.comQuantum Cyber Assumes Direct Manufacturing of Autonomous Drone; Expands BP United AgreementJune 2, 2026 | globenewswire.comQuantum Cyber Announces Plans to Establish U.S.-Based Defense-Technology Manufacturing Complex to Support Drone and Autonomous Systems DeliveryMay 28, 2026 | globenewswire.comQuantum Cyber Files Provisional Patent Application for Coaxial Dual-Propellant Grain Solid Rocket Motor Designed to Extend Range and Loiter Time of Defense UAVsMay 27, 2026 | globenewswire.comQuantum Cyber Strengthens Balance Sheet with Over $15 Million in Aggregate Financing; Cap Table is Debt-FreeMay 26, 2026 | globenewswire.comQuantum Cyber Files Provisional Patent with USPTO for Integrated Swarm Defense for Autonomous Ground VehiclesMay 21, 2026 | globenewswire.comQuantum Cyber Files Provisional Patent for Quantum-Navigated Amphibious Autonomous Ground Vehicle PlatformMay 20, 2026 | globenewswire.comQuantum Cyber Files Non-Provisional Patent Application With the USPTO for EMP-Shielding 3D-Printable Composite Filament for Drone and Defense ElectronicsMay 19, 2026 | globenewswire.comQuantum Cyber Files Patent with USPTO for Autonomous Naval Mine Countermeasure System Addressing Iran's Mining of the Strait of Hormuz and Trump Administration Homeland Security PrioritiesMay 19, 2026 | globenewswire.comQuantum Cyber forms US defense subsidiary for drone programsMay 19, 2026 | msn.comQuantum Cyber Launches Quantum Drones Corporation to Advance U.S. Federal Defense Procurement Strategy and Autonomous Warfare CapabilitiesMay 18, 2026 | globenewswire.comQuantum Cyber to Exhibit at Special Operations Forces Week 2026May 18, 2026 | globenewswire.comQuantum Cyber (QUCY) Stock Rockets 73% on Exclusive Drone Technology Licensing AgreementMay 15, 2026 | blockonomi.comQuantum Cyber N.V. Launches quantum-cyber.ai Targeting Homeland Security, Autonomous Drone, & Quantum Technology SectorsMay 15, 2026 | globenewswire.comQuantum Cyber Launches quantum-cyber.ai Targeting Homeland Security, Autonomous Drone, and Quantum Technology SectorsMay 15, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQUCY, ETHZ, BDTX, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$4.16 +0.10 (+2.46%) As of 06/12/2026Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Black Diamond Therapeutics NASDAQ:BDTX$1.75 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.57%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Flag Ship Acquisition NASDAQ:ETHZ$5.35 +0.06 (+1.13%) As of 06/12/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Mainz Biomed NASDAQ:QUCY$1.73 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.76 +0.03 (+2.02%) As of 06/12/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
